Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 9/20 | 0.46 |
| ▸ | CNR1 | P21554 | 8/20 | 0.46 |
| ▸ | SMPD1 | P17405 | 4/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9468619 | 0.86 | MAPT (0.42) | CNR2CYP1A2 | |
| SCHEMBL1231889 | 0.86 | CNR2 (0.42) | CNR2CNR1CYP1A2 | |
| SCHEMBL1233460 | 0.86 | CNR2 (0.37) | CNR2CYP1A2 | |
| SCHEMBL1233646 | 0.85 | CNR2 (0.38) | CNR2CNR1CYP1A2 | |
| SCHEMBL29834790 | 0.85 | CNR2 (0.46) | CNR2CNR1SMPD1CYP1A2 | |
| SCHEMBL4928436 | 0.83 | CNR1 (0.49) | CNR2CNR1SMPD1 | |
| SCHEMBL1234038 | 0.83 | CNR2 (0.36) | CNR2CNR1CYP1A2 | |
| SCHEMBL12100567 | 0.82 | CNR2 (0.45) | CNR2CNR1SMPD1 | |
| SCHEMBL1234279 | 0.82 | LMNA (0.36) | CYP1A2 | |
| SCHEMBL3219891 | 0.82 | CNR1 (0.48) | CNR2CNR1SMPD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1494673-B1 | COMPOUNDS HAVING UNIQUE CB1 RECEPTOR BINDING SELECTIVITY AND METHODS FOR THEIR PRODUCTION AND USE | RES TRIANGLE INST (US) | 2008-08-13 | — | — | EP | disclosed |
| EP-1494673-A4 | COMPOUNDS HAVING UNIQUE CB1 RECEPTOR BINDING SELECTIVITY AND METHODS FOR THEIR PRODUCTION AND USE | RES TRIANGLE INST (US) | 2006-01-18 | — | — | EP | disclosed |
| EP-1494673-A1 | COMPOUNDS HAVING UNIQUE CB1 RECEPTOR BINDING SELECTIVITY AND METHODS FOR THEIR PRODUCTION AND USE | RESEARCH TRIANGLE INSTITUTE (US) | 2005-01-12 | — | — | EP | disclosed |
| US-6825209-B2 | AN AMIDE DERIVATIVE USED AS CANNABINOID ANTAGONIST FOR THE TREATMENT OF OBESITY, SCHIZOPHRENIA, MEMORY DYSFUNCTION AND MARIJUANA ABUSE | RESEARCH TRIANGLE INSTITUTE | 2004-11-30 | — | — | US | disclosed |
| WO-2003088968-A1 | COMPOUNDS HAVING UNIQUE CB1 RECEPTOR BINDING SELECTIVITY AND METHODS FOR THEIR PRODUCTION AND USE | RESEARCH TRIANGLE INSTITUTE (US) | 2003-10-30 | — | — | WO | disclosed |
| US-20030199536-A1 | Compounds having unique CB1 receptor binding selectivity and methods for their production and use | RESEARCH TRIANGLE INSTITUTE (US) | 2003-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030199536-A1 | Compounds having unique CB1 receptor binding selectivity and methods for their production and use | CNR1, CNR2, GPR18 | CNR2 2/4885CNR1 1/4885SMPD1 433/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.